Novo Nordisk is a biotechnology business based in the US. Novo Nordisk shares (NVO.US) are listed on the NYSE and all prices are listed in US dollars. Its last market close was $122.75 – a decrease of 1.43% over the previous day. Novo Nordisk employs 63,370 staff and has a trailing 12-month revenue of around $232.3 billion.
Open your account.Provide your personal information and sign up.
Confirm your payment details.You'll need to fund your account with a bank transfer, debit card or credit card.
Search the platform for stock code:NVO in this case.
Research stocks.The platform should provide the latest information available.
Buy your stocks.Place a market order or limit order with your preferred number of shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.
Our selection of top picks is based on the same criteria as our annual Stock Trading Platform Awards. This is updated yearly to reflect changes in the market.
"Best for" picks are those we've evaluated to be best for specific product features or categories – you can read our full methodology here. If we show a "Promoted" pick, it's been chosen from among our commercial partners and is based on factors that include special features or offers, and the commission we receive.
This isn't an exhaustive list of all the trading platforms out there. What's best for you depends on your own investing strategy, budget and financial goals.
Is it a good time to buy Novo Nordisk stock?
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Use our graph to track the performance of NVO stocks over time.
Share price volatility
Over the last 12 months, Novo Nordisk's shares have ranged in value from as little as $74.9194 up to $137.573. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk's is 0.195. This would suggest that Novo Nordisk's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $122.75
1 week (2024-04-11)
-1.41%
1 month (2024-03-19)
-5.84%
3 months (2024-01-18)
14.76%
6 months (2023-10-19)
27.48%
1 year (2023-04-19)
-25.77%
2 years (2022-04-19)
6.24%
3 years (2021-04-19)
67.51%
5 years (2019-04-17)
153.67%
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Is Novo Nordisk under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Novo Nordisk P/E ratio, PEG ratio and EBITDA
Novo Nordisk's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Novo Nordisk stocks trade at around 46x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novo Nordisk's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3998. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Novo Nordisk's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $109.8 billion ($150.9 billion CAD).
The EBITDA is a measure of a Novo Nordisk's overall financial performance and is widely used to measure a its profitability.
Forward annual dividend yield: 1.12% of stock value
Dividend payout ratio: 2.27% of net profits
Novo Nordisk has recently paid out dividends equivalent to 1.12% of its share value annually.
Novo Nordisk has paid out, on average, around 2.27% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.12% return on their shares, in the form of dividend payments. In Novo Nordisk's case, that would currently equate to about 9.4 per share.
While Novo Nordisk's payout ratio might seem low, this can signify that the company is investing more in its future growth.
Novo Nordisk's most recent dividend payout was on 1 April 2024. The latest dividend was paid out to all shareholders who bought their shares by 21 March 2024 (the "ex-dividend date").
Currently 0.004% of Novo Nordisk shares are held by insiders and 9.297% by institutions.
Novo Nordisk's fiscal year ends in December.
Novo Nordisk's address is: Novo Alle 1, Bagsvaerd, Denmark, 2880
Novo Nordisk's shares were split on a 2:1 basis on 19 September 2023. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk shares which in turn could have impacted Novo Nordisk's share price.
It's as easy to sell Novo Nordisk as it is to buy! Here's how to sell Novo Nordisk stocks that you already own.
Open your investment app. If you've got one with desktop access, you can log in online
Go to your portfolio. This should be in the main menu
Find your shares. You may be able to search your portfolio
Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
Sell your Novo Nordisk shares. Your investment platform will let you know when your shares are sold
Most dealing providers will let you use your debit card to top up your account and buy shares. The main ways are with a debit card, bank transfer or with Apple/Google Pay.
The easiest way to get hold of some Novo Nordisk shares is to sign up for a stock trading app and place a market order or basic order. This type of order tells the platform that you're interested, so it'll try to execute it as quickly as it can. It could take some time for the order to go through, especially if there's a lot of volatility in Novo Nordisk shares.
Novo Nordisk financials
Revenue TTM
$232.3 billion
Operating margin TTM
42.79%
Gross profit TTM
$148.5 billion
Return on assets TTM
23.39%
Return on equity TTM
88.07%
Profit margin
36.03%
Book value
$23.90
Market capitalisation
$550.4 billion
TTM: trailing 12 months
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
A failed SPAC deal pulled the plug on this vertical farming company’s plans to go public. But you can buy stock in other sustainable farming companies.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser Disclosure
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
